Acquired hemophilia A associated with chronic myelomonocytic leukemia successfully treated by rituximab and azacitidine.

CONCLUSION: We report a case of acquired hemophilia A complicating a chronic myelomonocytic leukemia. Management with steroids, rituximab and azacitidine was successful. Useful of rituximab during acquired hemophilia is proposed. PMID: 29653879 [PubMed - as supplied by publisher]
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research

Related Links:

We report herein is such a rare case of acquired hemophilia in a patient with CLL.
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Source Type: research
We report herein is such a rare case of acquired hemophilia in a patient with CLL.
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Source Type: research
Roser Calvo* Patient Safety, Safety Science, AstraZeneca Pharmaceuticals, Gaithersburg, MD, United States Immune-related hematological adverse events are amongst the rare but potentially life-threatening complications of immune checkpoint inhibitors. The spectrum of these toxicities is broadening as the number of patients exposed to these agents is increasing. Yet, they are still relatively unknown to many clinicians, possibly due to a lack of specific diagnostic criteria, which poses a challenge for their recognition and proper reporting, and partly due to their low incidence, often too low to be noted in most c...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Authors: Alexander W Abstract We review key sessions on Hodgkin's lymphoma, diffuse large B-cell lymphoma, thromboembolism, hemophilia, sickle cell disease, and chronic lymphocytic leukemia. PMID: 29386868 [PubMed]
Source: P and T - Category: Drugs & Pharmacology Tags: P T Source Type: research
We report a hemorrhagic pericardial effusion as the AHA debut in a patient with untreated chronic lymphocytic leukemia and anticoagulated with apixaban for atrial fibrillation and chronic arterial ischemia. The patient was treated with recombinant activated factor VII to control the active bleeding and corticosteroids and cyclophosphamide to eradicate the inhibitor. In addition, a briefly review of hematological malignancies associated to acquired hemophilia was performed. Particularities: a) anticoagulant treatment may confuse the suspicion of AHA and its diagnosis; b) hemorrhagic pericardial effusion is an extremely r...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
We present a case of a 75-year-old man in whom both diseases were present simultaneously with life-threatening bleeding. This case is an example of the successful initial management and long-term treatment of acquired hemophilia A, warm autoimmune hemolytic anemia, and chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, prednisone, and cyclophosphamide. PMID: 28670081 [PubMed - in process]
Source: Baylor University Medical Center Proceedings - Category: Universities & Medical Training Authors: Tags: Proc (Bayl Univ Med Cent) Source Type: research
The field of Hematology is changing in many exciting ways. Since our time in training, we have seen the advent of new direct oral anticoagulants, targeted therapies in chronic myelogenous leukemia and B-cell lymphomas, and long-acting (and soon even longer duration) factor replacement in hemophilia. We have also seen improved risk stratification, maturing of reduced intensity and haploidentical stem-cell transplant, and the rebirth of gene therapy. These are changes that have improved the quality of life and survival of our patients.
Source: Primary Care: Clinics in Office Practice - Category: Primary Care Authors: Source Type: research
DISCUSSION: Although rituximab is not a standard therapy for AHA, it may be useful in resistant cases. However, the definitive place of this monoclonal antibody in the therapeutic strategy for AHA (first or second-line, alone or in combination with other drugs) remains to be determined more precisely and warrants further investigation. PMID: 26509821 [PubMed - as supplied by publisher]
Source: Blood Transfusion - Category: Hematology Authors: Tags: Blood Transfus Source Type: research
Source: Haemophilia - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research
Source: Haemophilia - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research
More News: Chronic Leukemia | Haemophilia | Hemophilia | Internal Medicine | Leukemia | Rituxan